Outcomes of transcatheter aortic valve replacement in patients with and without amyloidosis: A nationwide analysis from the United States

Amyloidosis is a common comorbidity in elderly patients with aortic stenosis (AS) referred for transcatheter aortic valve replacement (TAVR). This study aims to assess the impact of amyloidosis on the clinical outcomes of TAVR. This is a retrospective study of the National Inpatient Sample database...

Full description

Saved in:
Bibliographic Details
Published in:Cardiovascular revascularization medicine 2024-01, Vol.58, p.34-42
Main Authors: Ismayl, Mahmoud, Abbasi, Muhannad, Al-Abcha, Abdullah, El-Am, Edward, Alkhouli, Mohamad, Guerrero, Mayra, Dispenzieri, Angela, Nkomo, Vuyisile T., Abou Ezzeddine, Omar F., Grogan, Martha, Anavekar, Nandan S.
Format: Article
Language:English
Subjects:
Adult
Aged
Amyloidosis
Aortic stenosis
Aortic Valve - surgery
Aortic Valve Stenosis - complications
Aortic Valve Stenosis - diagnostic imaging
Aortic Valve Stenosis - surgery
Complications
Hospital Mortality
Humans
In-hospital mortality
Male
Postoperative Complications
Retrospective Studies
Risk Factors
TAVR
Transcatheter Aortic Valve Replacement
Treatment Outcome
United States - epidemiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Amyloidosis is a common comorbidity in elderly patients with aortic stenosis (AS) referred for transcatheter aortic valve replacement (TAVR). This study aims to assess the impact of amyloidosis on the clinical outcomes of TAVR. This is a retrospective study of the National Inpatient Sample database that identified adult patients (≥18 years) with AS hospitalized for TAVR from 2016 through 2020 to compare outcomes in those with versus without amyloidosis. Our primary outcome was in-hospital mortality. Secondary outcomes included procedural complications, hospital length of stay (LOS), and total costs. TAVR trends in both cohorts were also evaluated. The total cohort included 304,710 patients with AS undergoing TAVR, of whom 410 had amyloidosis. Over the study period, TAVR trends increased significantly in patients with and without amyloidosis (both ptrend 
ISSN:1553-8389
1878-0938
DOI:10.1016/j.carrev.2023.07.002